- Years of research have linked cigarette smoking to premature illness and death from multiple conditions including CVD. However, a new study found that dying of a heart attack or stroke may often be the first sign of CVD in some people who smoke.
- Researchers found that cardiovascular disease (CVD) was the leading complication among people who smoke cigarettes when compared with death from other causes, including lung cancer.
- Smoking was also linked to developing cardiovascular disease at a younger age and shortening a person’s lifespan by as much as four to five years.
Embargoed until 4 a.m. CT/5 a.m. ET Wednesday, Nov. 17, 2021
DALLAS, Nov. 17, 2021 — Death from a heart attack or stroke may be the first cardiovascular disease (CVD) event in some people who smoke cigarettes and CVD is the leading adverse health effect among smokers, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.
Decades of research links cigarette smoking to premature death caused by cardiovascular disease and other diseases such as lung cancer. According to the American Heart Association’s Heart and Stroke Statistical Update 2021, more than 480,000 U.S. adults die each year from cigarette smoking. Despite increasing awareness about the health benefits of quitting smoking, more than 34 million adults in the United States still smoke cigarettes.
“There is often more awareness and concern about cancer as a result of smoking than heart disease, so we wanted to better define the risks of smoking related to different types of cardiovascular disease and, most importantly, to cardiovascular death,” said lead study author Sadiya S. Kahn, M.D., M.Sc., an assistant professor of medicine in the division of cardiology at Northwestern University’s Feinberg School of Medicine in Chicago. “In our analysis, even after adjusting for deaths not related to the heart, such as those due to lung cancer, we found that fatal or non-fatal events related to cardiovascular disease are more likely to occur among people who smoke.”
The researchers pooled data from nine long-term cohort studies in the U.S. to evaluate multiple lifestyle factors as well as cardiovascular and other health outcomes. The analysis included data from 106,165 adults (50.4% women; 16.2% Black adults; 50.1% cigarette smokers) between the ages of 20 and 79, who were free of cardiovascular disease at the start of the studies. The new analysis categorized participants by smoking status (either yes or no, self-reported at study enrollment); age (young: 20 to 39 years of age; middle-aged: 40 to 59; and older: 60 to 79); and sex.
Using the combined data, researchers estimated the number of years lived with and without cardiovascular disease according to smoking status and then examined the association between smoking and cardiovascular events after accounting for death from other diseases such as lung cancer. Adjustments were made for age, race, body mass index (BMI), blood pressure and cholesterol levels. The follow-up time for study participants ranged from 10 to 25 years.
The biggest differences in risks and in deaths between the participants who smoked and those who didn’t smoke occurred during middle age. The analysis found:
- Middle-aged women who smoked were nearly twice as likely as non-smoking women to have a fatal CVD event as their first sign of CVD.
- Middle-aged men who smoked had a 79% chance of having a fatal CVD event as their first sign of cardiovascular disease – about 1.5 times more likely compared to middle-aged men who did not smoke.
- For middle-aged women, the long-term rates of CVD risk were nearly 10% higher in those who smoked compared to those who didn’t (34.7% for smokers; 24.8% for non-smokers).
- Middle-aged men who smoked had a more than 10% higher long-term risk for cardiovascular disease then men who didn’t smoke (46% for smokers; 35.8% for men non-smokers).
- Smoking was associated with the development of cardiovascular disease at an earlier age, by five years in middle-aged men and nearly four years in middle-aged women. Similar results were seen in younger and older adults, so that a greater number of years lived without CVD was seen across all non-smoking participants in all age and sex groups.
“Our findings note that preventing a heart attack, stroke or heart failure is vital, yet preventing unexpected sudden death as the first manifestation of cardiovascular disease is clearly a priority. People who smoke may not realize the harm cigarettes are causing their body until it’s too late,” Khan said. “Another notable finding among people who smoked was the early onset of CVD, and among those who developed CVD, how much younger they were. There’s not a lot of research on young adults who smoke, particularly among young men. Our study adds important perspective.”
Among young adults, 20 to 39 years of age, the analysis found:
- The risk for CVD started to increase significantly in young men who smoked near the 10-year follow-up mark, while in young women the increased risk for CVD in those who smoked became more evident near the 20-year follow-up mark.
- With respect to CVD subtypes, young men who smoked had the highest long-term risk for heart attacks (24%), while young women had the highest long-term risk (11.3%) for other CVD causes of death, such as stroke or heart failure.
Among all age groups, a majority of the first CVD events were fatal or nonfatal heart attack. Fatal and nonfatal strokes were the next leading causes of first CVD event among those in the young age group. Heart failure was the second leading cause among the middle-aged and older age groups.
Khan said these results emphasize the contribution of smoking to the earlier onset of CVD overall, and also affected excess CVD risk well into the eighth decade of life in both men and women, even after adjusting for the competing risk of non-CVD death.
Based on these results, the researchers suggest that all people who smoke should talk with their physicians or other health care professionals about taking steps toward quitting and improving their cardiovascular health.
“Smoking cessation is very challenging and reaching out to your doctor or other health care professionals for support and resources is important – the sooner the better,” Khan said. “This earlier onset of heart disease and stroke is very crucial to think about with aging and the already known complications of aging.”
There were a few limitations to the study. Smoking status was based on the participants’ report at the beginning of the study, so some could have stopped or started smoking during the follow-up, which would not have been included. Khan also noted that they were not able to account for more specifics about the people who smoked, such as the number of years participants smoked, the number of cigarettes smoked per day or whether people who had previously smoked were included in the studies.
“Despite these limitations, the findings are quite significant,” Khan said.
“These results offer a very compelling message that people who smoke need to hear – smoking can kill you before you even know you have cardiovascular disease. It can, indeed, be a silent killer,” said Esa M. Davis, M.D., a member of the American Heart Association’s Council on Lifestyle and Cardiometabolic Health, associate professor of medicine and the clinical and translational science medical director of the tobacco treatment service of the University of Pittsburgh Medical Center, who was not involved in the study. “Heart attacks, strokes and other types of cardiovascular disease don’t always have early symptoms, so if you don’t know you have CVD, it can’t be treated. You can help prevent CVD by never smoking or stopping smoking as soon as possible.”
The American Heart Association supports ending the use of all combustible tobacco products while ensuring other tobacco products such as electronic cigarettes do not addict the next generation of youth and adolescents. In 2019, the Association announced $20 million in research funding to drive scientific discovery that will help end teen tobacco use and nicotine addiction in the U.S. Additionally, the Association’s Tobacco Center of Regulatory Science is now in its second round of funding from the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) to study the cardiovascular effects of tobacco and nicotine products, including e-cigarettes and other non-traditional devices. Basic and population research supported by the Center will help develop further understanding relevant to the potential regulation of current, new and emerging tobacco and nicotine products.
Co-authors are Hongyan Ning, M.D., M.S.; Arjun Sinha, M.D.; John Wilkins, M.D.; Norrina B. Allen, Ph.D.; Thanh Huyen T. Vu, M.D., Ph.D.; Jarett D. Berry, M.D., FAHA; Donald M. Lloyd-Jones, M.D., Sc.M., FAHA; and Ranya Sweis M.D., M.Sc.
The National Institutes of Health's National Heart, Lung, and Blood Institute and National Center for Advancing Translational Sciences, and the American Heart Association funded the study.
- Multimedia is available on the right column of release link https://newsroom.heart.org/news/fatal-heart-attack-or-stroke-could-be-first-sign-of-cvd-in-some-smokers?preview=cdbe0fa70c4b851fdd3915b0d869263b
- After Nov. 17, view the manuscript online.
- Leading global cardiovascular organizations release joint opinion on achieving the ‘tobacco endgame’
- How Smoking and Nicotine Damage Your Body
- American Heart Association Presidential Advisory: New and Emerging Tobacco Products and the Nicotine Endgame
- The American Heart Association’s Tobacco Endgame movement
- Follow AHA/ASA news on Twitter @HeartNews
- Follow news from the Journal of the American Heart Association @JAHA_AHA
Statements and conclusions of studies published in the American Heart Association’s scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Cathy Lewis: 214-706-1324; firstname.lastname@example.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)